Wyszuk. zaawans.

Tom 1, Nr 3 (2023)
Artykuł przeglądowy
Opublikowany online: 2024-01-05
Dodaj do koszyka: 49,00 PLN
Wyświetlenia strony 218
Wyświetlenia/pobrania artykułu 3

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Łuszczyca w populacji dziecięcej — choroby współistniejące z łuszczycą

Magdalena Szczegielniak1, Aleksandra Lesiak1, Joanna Narbutt1
Dermatologia w Praktyce Klinicznej 2023;1(3):91-100.

Streszczenie

Łuszczyca jest przewlekłą, niezakaźną, przebiegającą z okresami zaostrzeń i remisji zapalną chorobą skory o podłożu immunologicznym. Pacjenci chorujący na łuszczycę w populacji osob dorosłych są predysponowani do rozwoju schorzeń sercowo-naczyniowych, zespołu metabolicznego i jego składowych, cukrzycy typu 2 i chorob zapalnych jelit. U prawie jednej trzeciej pacjentow pierwsze objawy łuszczycy pojawiają się w dzieciństwie. Wczesna identyfikacja czynnikow ryzyka chorob towarzyszących lub wykrycie ich na początkowym etapie zaawansowania może zmniejszyć prawdopodobieństwo ich rozwoju w wieku dorosłym. Łuszczyca może mieć negatywny wpływ na zdrowie psychiczne, jakość życia oraz na funkcjonowanie w życiu szkolnym i w środowisku rowieśniczym. W pracy dokonano przeglądu aktualnego stanu wiedzy na temat chorob towarzyszących łuszczycy w populacji dziecięcej.

Słowa kluczowe: łuszczycadziecichoroby współistniejące

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Espinosa M, Gottlieb BS. Juvenile idiopathic arthritis. Pediatr Rev. 2012; 33(7): 303–313.
    CrossRefPubMed
  2. Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004; 17(5): 364–375.
    CrossRefPubMed
  3. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015; 41(4): 545–568.
    CrossRefPubMed
  4. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011; 23(5): 437–443.
    CrossRefPubMed
  5. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391(10136): 2273–2284.
    CrossRefPubMed
  6. Gottlieb AB, Merola JF. Axial psoriatic arthritis: An update for dermatologists. J Am Acad Dermatol. 2021; 84(1): 92–101.
    CrossRefPubMed
  7. Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020; 31(7): 662–679.
    CrossRefPubMed
  8. Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018; 391(10136): 2285–2294.
    CrossRefPubMed
  9. Gisondi P, Fostini AC, Fossà I, et al. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018; 36(1): 21–28.
    CrossRefPubMed
  10. Zimmet P, Alberti G, Kaufman F, et al. International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes. The metabolic syndrome in children and adolescents. Lancet. 2007; 369(9579): 2059–2061.
    CrossRefPubMed
  11. Milčić D, Janković S, Vesić S, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol. 2017; 92(1): 46–51.
    CrossRefPubMed
  12. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018; 36(1): 14–20.
    CrossRefPubMed
  13. Stefanadi EC, Dimitrakakis G, Antoniou CK, et al. Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. Diabetol Metab Syndr. 2018; 10: 9.
    CrossRefPubMed
  14. Fanning E, O'Shea D. Genetics and the metabolic syndrome. Clin Dermatol. 2018; 36(1): 9–13.
    CrossRefPubMed
  15. Steele CE, Morrell D, Evans M. Metabolic syndrome and inflammatory skin conditions. Curr Opin Pediatr. 2019; 31(4): 515–522.
    CrossRefPubMed
  16. Furue M, Kadono T. "Inflammatory skin march" in atopic dermatitis and psoriasis. Inflamm Res. 2017; 66(10): 833–842.
    CrossRefPubMed
  17. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012; 132(3 Pt 1): 556–562.
    CrossRefPubMed
  18. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013; 68(4): 654–662.
    CrossRefPubMed
  19. Osier E, Wang AS, Tollefson MM, et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017; 153(7): 698–704.
    CrossRefPubMed
  20. Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015; 2: 1.
    CrossRefPubMed
  21. Goldminz AM, Buzney CD, Kim N, et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol. 2013; 30(6): 700–705.
    CrossRefPubMed
  22. Rodríguez-Zúñiga MJ, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017; 77(4): 657–666.e8.
    CrossRefPubMed
  23. Au Sc, Goldminz AM, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol. 2012; 66(6): 1012–1013.
    CrossRefPubMed
  24. Małecka-Tendera E, Zachurzok-Buczyńska A. Otyłość i zespół metaboliczny u dzieci i młodzieży – epidemiologia, klasyfikacja i leczenie. In: Podolec P. ed. Podręcznik Polskiego Forum Profilaktyki. T.2.Małecka-Tendera E, Zachurzok-Buczyńska A. ed. Medycyna Praktyczna, Kraków 2010: 209–221.
  25. Zimmet P, Alberti KG, Kaufman F, et al. IDF Consensus Group. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007; 8(5): 299–306.
    CrossRefPubMed
  26. Jańczyk W, Litwin M, Socha P. Co to jest zespół metaboliczny u dzieci? Stand Med/Pediatria. 2010; 7: 23–25.
  27. Caroppo F, Galderisi A, Ventura L, et al. Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis. Eur J Pediatr. 2021; 180(6): 1739–1745.
    CrossRefPubMed
  28. Pietrzak A, Grywalska E, Walankiewicz M, et al. Psoriasis and metabolic syndrome in children: current data. Clin Exp Dermatol. 2017; 42(2): 131–136.
    CrossRefPubMed
  29. Mahé E, Maccari F, Beauchet A, et al. GEM Resopso. Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. Br J Dermatol. 2013; 169(4): 889–895.
    CrossRefPubMed
  30. Aalemi AK, Hamdard AG, Chen H. Association of metabolic syndrome with pediatric psoriasis: a case-control study in Kabul, Afghanistan. Int J Dermatol. 2020; 59(4): 451–456.
    CrossRefPubMed
  31. Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation. 2005; 111(15): 1999–2012.
    CrossRefPubMed
  32. Gutmark-Little I, Shah KN. Obesity and the metabolic syndrome in pediatric psoriasis. Clin Dermatol. 2015; 33(3): 305–315.
    CrossRefPubMed
  33. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008; 19(1): 5–21.
    CrossRefPubMed
  34. Sterry W, Strober BE, Menter A, et al. International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007; 157(4): 649–655.
    CrossRefPubMed
  35. Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis. Br J Dermatol. 2009; 161(2): 484–486.
    CrossRefPubMed
  36. Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014; 150(5): 573–574.
    CrossRefPubMed
  37. Duarte GV, Oliveira Md, Cardoso TM, et al. Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol. 2013; 52(2): 177–181.
    CrossRefPubMed
  38. Kong Yi, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019; 18(1): 171.
    CrossRefPubMed
  39. Duarte GV, Oliveira Md, Cardoso TM, et al. Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol. 2013; 52(2): 177–181.
    CrossRefPubMed
  40. Ergun T, Seckin Gencosmanoglu D, Karakoc-Aydiner E, et al. Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression. Australas J Dermatol. 2017; 58(4): e182–e187.
    CrossRefPubMed
  41. Guidolin L, Borin M, Fontana E, et al. Central obesity in children with psoriasis. Acta Derm Venereol. 2018; 98(2): 282–283.
    CrossRefPubMed
  42. Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013; 149(2): 166–176.
    CrossRefPubMed
  43. Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011; 159(4): 577–583.
    CrossRefPubMed
  44. Mahé E, Beauchet A, Bodemer C, et al. Groupe de Recherche de la Société Française de Dermatologie Pédiatrique. Psoriasis and obesity in French children: a case-control, multicentre study. Br J Dermatol. 2015; 172(6): 1593–1600.
    CrossRefPubMed
  45. Jensen P, Skov L. Psoriasis and Obesity. Dermatology. 2016; 232(6): 633–639.
    CrossRefPubMed
  46. Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes (Lond). 2015; 39(8): 1197–1202.
    CrossRefPubMed
  47. Akhyani M, Ehsani AH, Robati RM, et al. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007; 21(10): 1330–1332.
    CrossRefPubMed
  48. Ma C, Harskamp CT, Armstrong EJ, et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013; 168(3): 486–495.
    CrossRefPubMed
  49. Tom WL, Playford MP, Admani S, et al. Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile. J Invest Dermatol. 2016; 136(1): 67–73.
    CrossRefPubMed
  50. Moudgil S, Mahajan R, Narang T, et al. Central obesity and dyslipidemia in pediatric patients with psoriasis: An observational study from India. J Am Acad Dermatol. 2021; 85(6): 1655–1657.
    CrossRefPubMed
  51. Miller IM, Skaaby T, Ellervik C, et al. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol. 2013; 169(6): 1180–1187.
    CrossRefPubMed
  52. Shahwan KT, Kimball AB. Psoriasis and cardiovascular disease. Med Clin North Am. 2015; 99(6): 1227–1242.
    CrossRefPubMed
  53. Ma L, Li Me, Wang H, et al. High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China. Arch Dermatol Res. 2014; 306(3): 247–251.
    CrossRefPubMed
  54. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009; 145(6): 700–703.
    CrossRefPubMed
  55. Mansouri B, Kivelevitch D, Natarajan B, et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes. JAMA Dermatol. 2016; 152(11): 1244–1253.
    CrossRefPubMed
  56. Boehncke WH, Boehncke S, Tobin AM, et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20(4): 303–307.
    CrossRefPubMed
  57. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978; 99(5): 469–475.
    CrossRefPubMed
  58. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013; 2(2): e000062.
    CrossRefPubMed
  59. Tablazon ILD, Al-Dabagh A, Davis SA, et al. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol. 2013; 14(1): 1–7.
    CrossRefPubMed
  60. Evensen K, Slevolden E, Skagen K, et al. Increased subclinical atherosclerosis in patients with chronic plaque psoriasis. Atherosclerosis. 2014; 237(2): 499–503.
    CrossRefPubMed
  61. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011; 124(8): 775.e1–775.e6.
    CrossRefPubMed
  62. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010; 31(8): 1000–1006.
    CrossRefPubMed
  63. Dey AK, Joshi AA, Chaturvedi A, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol. 2017; 2(9): 1013–1018.
    CrossRefPubMed
  64. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009; 129(10): 2411–2418.
    CrossRefPubMed
  65. Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res. 2017; 309(3): 225–228.
    CrossRefPubMed
  66. Kwa MC, Silverberg JI. Association between inflammatory skin disease and cardiovascular and cerebrovascular co-morbidities in US adults: analysis of nationwide inpatient sample data. Am J Clin Dermatol. 2017; 18(6): 813–823.
    CrossRefPubMed
  67. Hu SCS, Lan CCE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017; 18(10).
    CrossRefPubMed
  68. Furue M, Tsuji G, Chiba T, et al. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. Intern Med. 2017; 56(13): 1613–1619.
    CrossRefPubMed
  69. Lin HW, Wang KH, Lin HC, et al. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011; 64(3): 495–501.
    CrossRefPubMed
  70. Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol. 2012; 166(4): 811–818.
    CrossRefPubMed
  71. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015; 74(2): 326–332.
    CrossRefPubMed
  72. Wu JJ, Choi YM, Bebchuk JD. Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. J Dermatolog Treat. 2015; 26(3): 230–234.
    CrossRefPubMed
  73. Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in canadian patients with psoriasis: a retrospective cohort study. J Cutan Med Surg. 2013; 17(6): 398–403.
    CrossRefPubMed
  74. Shiba M, Kato T, Funasako M, et al. Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan. PLoS One. 2016; 11(2): e0149316.
    CrossRefPubMed
  75. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14): 1735–1741.
    CrossRefPubMed
  76. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008; 159(4): 895–902.
    CrossRefPubMed
  77. Egeberg A, Thyssen JP, Jensen P, et al. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. Acta Derm Venereol. 2017; 97(7): 819–824.
    CrossRefPubMed
  78. Dhaher SA, Alyassiry F. Screening for comorbid cardiovascular risk factors in pediatric psoriasis among iraqi patients: a case-control study. Cureus. 2021; 13(9): e18397.
    CrossRefPubMed
  79. Kwa L, Kwa MC, Silverberg JI. Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States. J Am Acad Dermatol. 2017; 77(6): 1023–1029.
    CrossRefPubMed
  80. Fabi M, Chessa MA, Panizza D, et al. Psoriasis and cardiovascular risk in children: the usefulness of carotid intima-media thickness. Pediatr Cardiol. 2022; 43(7): 1462–1470.
    CrossRefPubMed
  81. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015; 33(1): 41–55.
    CrossRefPubMed
  82. Lai YiC, Yew YW. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. J Cutan Med Surg. 2016; 20(4): 327–333.
    CrossRefPubMed
  83. Benson MM, Frishman WH. The heartbreak of psoriasis: a review of cardiovascular risk in patients with psoriasis. Cardiol Rev. 2015; 23(6): 312–316.
    CrossRefPubMed
  84. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010; 163(3): 586–592.
    CrossRefPubMed
  85. Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014; 150(9): 957–963.
    CrossRefPubMed
  86. Armesto S, Coto-Segura P, Osuna CG, et al. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol. 2012; 26(6): 785–788.
    CrossRefPubMed
  87. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010; 90(1): 23–26.
    CrossRefPubMed
  88. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013; 31(3): 433–42; discussion 442.
    CrossRefPubMed
  89. Abedini R, Najafi MT, Azizpour A, et al. Hypertension in psoriasis patients: based on office and ambulatory blood pressure measurement. Blood Press Monit. 2020; 25(6): 351–354.
    CrossRefPubMed
  90. Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013; 69(6): 1014–1024.
    CrossRefPubMed
  91. Hu MY, Yang Q, Zheng J. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms. Clin Exp Dermatol. 2020; 45(7): 836–840.
    CrossRefPubMed
  92. Su YS, Yu HS, Li WC, et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. J Eur Acad Dermatol Venereol. 2013; 27(7): 876–883.
    CrossRefPubMed
  93. Caroppo F, Ventura L, Belloni Fortina A. High blood pressure in normal-weight children with psoriasis. Acta Derm Venereol. 2019; 99(3): 329–330.
    CrossRefPubMed
  94. Shah K, Mellars L, Changolkar A, et al. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017; 77(2): 287–292.e4.
    CrossRefPubMed
  95. Dregan A, Charlton J, Chowienczyk P, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014; 130(10): 837–844.
    CrossRefPubMed
  96. Papagrigoraki A, Del Giglio M, Cosma C, et al. Advanced glycation end products are increased in the skin and blood of patients with severe psoriasis. Acta Derm Venereol. 2017; 97(7): 782–787.
    CrossRefPubMed
  97. Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014; 53(2): 346–352.
    CrossRefPubMed
  98. Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers. Front Med (Lausanne). 2021; 8: 605691.
    CrossRefPubMed
  99. Holm JG, Thomsen SF. Type 2 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 2019; 9: 1–6.
    CrossRefPubMed
  100. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013; 149(1): 84–91.
    CrossRefPubMed
  101. Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol. 2014; 70(4): 691–698.
    CrossRefPubMed
  102. Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: A prospective population-based cohort study. J Am Acad Dermatol. 2018; 78(2): 315–322.e1.
    CrossRefPubMed
  103. Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant. J Am Acad Dermatol. 2015; 72(4): 599–605.
    CrossRefPubMed
  104. Bajaj S, Mandal S, Singh KG, et al. Metabolic diseases and associated complications in patients with psoriasis. J Assoc Physicians India. 2020; 68(10): 44–46.
    PubMed
  105. Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015; 231(1): 35–40.
    CrossRefPubMed
  106. Dhara S, Dasgupta A, Rout JK, et al. Clinico-biochemical correlation between psoriasis and insulin resistance. Indian J Clin Biochem. 2015; 30(1): 99–103.
    CrossRefPubMed
  107. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018; 9: 579.
    CrossRefPubMed
  108. Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 2017; 26(11): 1112–1117.
    CrossRefPubMed
  109. Gisondi P, Bellinato F, Girolomoni G, et al. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020; 11: 117.
    CrossRefPubMed
  110. Granata M, Skarmoutsou E, Trovato C, et al. Obesity, type 1 diabetes, and psoriasis: an autoimmune triple flip. Pathobiology. 2017; 84(2): 71–79.
    CrossRefPubMed
  111. Vashist S, Mahajan VK, Mehta KS, et al. Association of psoriasis with autoimmune disorders: results of a pilot study. Indian Dermatol Online J. 2020; 11(5): 753–759.
    CrossRefPubMed
  112. Krawczyk A, Miśkiewicz J, Strzelec K, et al. Apoptosis in autoimmunological diseases, with particular consideration of molecular aspects of psoriasis. Med Sci Monit. 2020; 26: e922035.
    CrossRefPubMed
  113. Caroppo F, Galderisi A, Moretti C, et al. Prevalence of psoriasis in a cohort of children and adolescents with type 1 diabetes. J Eur Acad Dermatol Venereol. 2021; 35(9): e589–e591.
    CrossRefPubMed
  114. Armstrong AW, Guérin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015; 72(6): 968–77.e2.
    CrossRefPubMed
  115. Ip W, Kirchhof MG. Glycemic control in the treatment of psoriasis. Dermatology. 2017; 233(1): 23–29.
    CrossRefPubMed
  116. Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012; 26(5): 644–650.
    CrossRefPubMed
  117. Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018; 154(12): 1417–1423.
    CrossRefPubMed
  118. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016; 175(3): 487–492.
    CrossRefPubMed
  119. Bar Yehuda S, Axlerod R, Toker O, et al. The association of inflammatory bowel diseases with autoimmune disorders: a report from the epi-IIRN. J Crohns Colitis. 2019; 13(3): 324–329.
    CrossRefPubMed
  120. Burisch J, Jess T, Egeberg A. Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in denmark. Clin Gastroenterol Hepatol. 2019; 17(13): 2704–2712.e3.
    CrossRefPubMed
  121. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008; 8(6): 458–466.
    CrossRefPubMed
  122. Pietrzak D, Pietrzak A, Krasowska D, et al. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017; 309(9): 679–693.
    CrossRefPubMed
  123. Bezzio C, Della Corte C, Vernero M, et al. Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. Therap Adv Gastroenterol. 2022; 15: 17562848221115312.
    CrossRefPubMed
  124. Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013; 2013: 983902.
    CrossRefPubMed
  125. Hsu LN, Armstrong AW. Psoriasis and autoimmune disorders: a review of the literature. J Am Acad Dermatol. 2012; 67(5): 1076–1079.
    CrossRefPubMed
  126. Wu JJ, Nguyen TU, Poon KYT, et al. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012; 67(5): 924–930.
    CrossRefPubMed
  127. Ojetti V, Aguilar Sanchez J, Guerriero C, et al. High prevalence of celiac disease in psoriasis. Am J Gastroenterol. 2003; 98(11): 2574–2575.
    CrossRefPubMed
  128. Ludvigsson JF, Lindelöf B, Zingone F, et al. Psoriasis in a nationwide cohort study of patients with celiac disease. J Invest Dermatol. 2011; 131(10): 2010–2016.
    CrossRefPubMed
  129. Birkenfeld S, Dreiher J, Weitzman D, et al. Coeliac disease associated with psoriasis. Br J Dermatol. 2009; 161(6): 1331–1334.
    CrossRefPubMed
  130. De Bastiani R, Gabrielli M, Lora L, et al. Association between coeliac disease and psoriasis: Italian primary care multicentre study. Dermatology. 2015; 230(2): 156–160.
    CrossRefPubMed
  131. Ungprasert P, Wijarnpreecha K, Kittanamongkolchai W. Psoriasis and risk of celiac disease: a systematic review and meta-analysis. Indian J Dermatol. 2017; 62(1): 41–46.
    CrossRefPubMed
  132. Juzlova K, Votrubova J, Dzambova M, et al. Gastrointestinal comorbidities in patients with psoriasis in the Czech Republic: The results of 189 patients with psoriasis and 378 controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016; 160(1): 100–105.
    CrossRefPubMed
  133. Acharya P, Mathur M. Association between psoriasis and celiac disease: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 82(6): 1376–1385.
    CrossRefPubMed
  134. Bhatia BK, Millsop JW, Debbaneh M, et al. Diet and psoriasis, part II: celiac disease and role of a gluten-free diet. J Am Acad Dermatol. 2014; 71(2): 350–358.
    CrossRefPubMed
  135. Akbulut S, Gür G, Topal F, et al. Coeliac disease-associated antibodies in psoriasis. Ann Dermatol. 2013; 25(3): 298–303.
    CrossRefPubMed
  136. Kolchak NA, Tetarnikova MK, Theodoropoulou MS, et al. Prevalence of antigliadin IgA antibodies in psoriasis vulgaris and response of seropositive patients to a gluten-free diet. J Multidiscip Healthc. 2018; 11: 13–19.
    CrossRefPubMed
  137. Dhattarwal N, Mahajan VK, Mehta KS, et al. The association of anti-gliadin and anti-transglutaminase antibodies and chronic plaque psoriasis in Indian patients: Preliminary results of a descriptive cross-sectional study. Australas J Dermatol. 2020; 61(4): e378–e382.
    CrossRefPubMed
  138. Michaëlsson G, Gerdén B, Ottosson M, et al. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol. 1993; 129(6): 667–673.
    CrossRefPubMed
  139. Kalayciyan A, Kotogyan A. Psoriasis, enteropathy and antigliadin antibodies. Br J Dermatol. 2006; 154(4): 778–779.
    CrossRefPubMed
  140. Nagui N, El Nabarawy E, Mahgoub D, et al. Estimation of (IgA) anti-gliadin, anti-endomysium and tissue transglutaminase in the serum of patients with psoriasis. Clin Exp Dermatol. 2011; 36(3): 302–304.
    CrossRefPubMed
  141. Damasiewicz-Bodzek A, Wielkoszyński T. Serologic markers of celiac disease in psoriatic patients. J Eur Acad Dermatol Venereol. 2008; 22(9): 1055–1061.
    CrossRefPubMed
  142. Egeberg A, Griffiths CEM, Mallbris L, et al. The association between psoriasis and coeliac disease. Br J Dermatol. 2017; 177(6): e329–e330.
    CrossRefPubMed
  143. Kia KF, Nair RP, Ike RW, et al. Prevalence of antigliadin antibodies in patients with psoriasis is not elevated compared with controls. Am J Clin Dermatol. 2007; 8(5): 301–305.
    CrossRefPubMed
  144. Heitmann J, Frings VG, Geier A, et al. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? J Dtsch Dermatol Ges. 2021; 19(4): 517–528.
    CrossRefPubMed
  145. Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018; 179(1): 16–29.
    CrossRefPubMed
  146. Balak DMW, Piaserico S, Kasujee I. Non-Alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Psoriasis (Auckl). 2021; 11: 151–168.
    CrossRefPubMed
  147. Ramos AN, de Oliveira Rocha B, de Almeida Rêgo VR, et al. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review. Acta Dermatovenerol Croat. 2014; 22(2): 132–136.
    PubMed
  148. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011; 25(4): 383–391.
    CrossRefPubMed
  149. Ganzetti G, Campanati A, Molinelli E, et al. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol. 2016; 8(2): 120–131.
    CrossRefPubMed
  150. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol. 2015; 7(3): 315–326.
    CrossRefPubMed
  151. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009; 51(4): 758–764.
    CrossRefPubMed
  152. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012; 53(3): 190–197.
    CrossRefPubMed
  153. Klujszo EH, Parcheta P, Witkowska AB, et al. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol. 2020; 37(4): 468–474.
    CrossRefPubMed
  154. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016; 30(2): 282–287.
    CrossRefPubMed
  155. Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015; 29(4): 656–662.
    CrossRefPubMed
  156. Ruan Z, Lu T, Chen Y, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022; 158(7): 745–753.
    CrossRefPubMed
  157. Bellinato F, Gisondi P, Mantovani A, et al. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022; 45(7): 1277–1288.
    CrossRefPubMed
  158. Valenzuela F, De La Cruz C, Lecaros C, et al. Comorbidities in Chilean patients with psoriasis: a global healthcare study on psoriasis. Clin Exp Dermatol. 2022; 47(12): 2234–2241.
    CrossRefPubMed
  159. van der Voort EAM, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014; 70(3): 517–524.
    CrossRefPubMed
  160. Abedini R, Salehi M, Lajevardi V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015; 40(7): 722–727.
    CrossRefPubMed
  161. Yang JJ, Nguyen KA, Fleischman MW, et al. Psoriasis in liver disease: Associations beyond nonalcoholic fatty liver disease. J Am Acad Dermatol. 2022; 86(4): 883–885.
    CrossRefPubMed
  162. Gau SY, Huang KH, Lee CH, et al. Bidirectional association between psoriasis and nonalcoholic fatty liver disease: real-world evidence from two longitudinal cohort studies. Front Immunol. 2022; 13: 840106.
    CrossRefPubMed
  163. Torbator K, Poo S, Al-Rubaye T, et al. Whether screening for non-alcoholic fatty liver disease in patients with psoriasis is necessary: a pilot quality improvement project. Cureus. 2022; 14(5): e24714.
    CrossRefPubMed
  164. Ortolan A, Lorenzin M, Tadiotto G, et al. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol. 2019; 38(10): 2843–2850.
    CrossRefPubMed
  165. Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM, et al. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: A cross-sectional cohort study. Australas J Dermatol. 2020; 61(2): 105–109.
    CrossRefPubMed
  166. Phan K, Onggo J, Charlton O, et al. Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis. Australas J Dermatol. 2019; 60(4): e352–e355.
    CrossRefPubMed
  167. van der Voort EAM, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the rotterdam study. Acta Derm Venereol. 2016; 96(2): 213–217.
    CrossRefPubMed
  168. Prussick R, Prussick L, Nussbaum D. Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to know. J Clin Aesthet Dermatol. 2015; 8(3): 43–45.
    PubMed
  169. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009; 51(4): 778–786.
    CrossRefPubMed
  170. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010; 146(8): 891–895.
    CrossRefPubMed
  171. Leisner MZ, Riis JL, Schwartz S, et al. Psoriasis and risk of mental disorders in denmark. JAMA Dermatol. 2019; 155(6): 745–747.
    CrossRefPubMed
  172. Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009-2012. JAMA Dermatol. 2016; 152(1): 73–79.
    CrossRefPubMed
  173. Rabin F, Bhuiyan SI, Islam T, et al. Psychiatric and psychological comorbidities in patients with psoriasis- a review. Mymensingh Med J. 2012; 21(4): 780–786.
    PubMed
  174. Kimball AB, Wu EQ, Guérin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012; 67(4): 651–657.e1.
    CrossRefPubMed
  175. Todberg T, Egeberg A, Jensen P, et al. Psychiatric comorbidities in children and adolescents with psoriasis: a population-based cohort study. Br J Dermatol. 2017; 177(2): 551–553.
    CrossRefPubMed
  176. Remröd C, Sjöström K, Svensson A. Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis. Br J Dermatol. 2013; 169(2): 344–350.
    CrossRefPubMed
  177. Simonić E, Kaštelan M, Peternel S, et al. Childhood and adulthood traumatic experiences in patients with psoriasis. J Dermatol. 2010; 37(9): 793–800.
    CrossRefPubMed
  178. Mitchell AE. Bidirectional relationships between psychological health and dermatological conditions in children. Psychol Res Behav Manag. 2018; 11: 289–298.
    CrossRefPubMed
  179. Bilgic A, Bilgic Ö, Akış HK, et al. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010; 27(6): 614–617.
    CrossRefPubMed
  180. Snast I, Reiter O, Atzmony L, et al. Psychological stress and psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2018; 178(5): 1044–1055.
    CrossRefPubMed
  181. Kara T, Topkarcı Z, Yılmaz S, et al. Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study. J Dermatolog Treat. 2019; 30(2): 129–134.
    CrossRefPubMed
  182. Koo JY, Do JH, Lee CS. Psychodermatology. J Am Acad Dermatol. 2000; 43(5 Pt 1): 848–853.
    CrossRefPubMed
  183. Patel KR, Lee HH, Rastogi S, et al. Association of psoriasis with psychiatric hospitalization in united states children and adults. Dermatology. 2019; 235(4): 276–286.
    CrossRefPubMed
  184. Manzoni AP, Weber MB, Nagatomi AR, et al. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2013; 88(6): 894–899.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna